Description of BCG and Tuberculosis Disease in a Cohort of 79 Patients with Chronic Granulomatous Disease.

Humans Granulomatous Disease, Chronic / diagnosis BCG Vaccine / adverse effects Male Female Child Tuberculosis / epidemiology Child, Preschool Infant Adolescent NADPH Oxidase 2 / genetics Cohort Studies Mycobacterium bovis Mexico / epidemiology Antitubercular Agents / therapeutic use NADPH Oxidases / genetics

Bacillus Calmette–Guérin Chronic granulomatous disease Mycobacteria Tuberculosis

Journal

Journal of clinical immunology

ISSN: 1573-2592

Titre abrégé: J Clin Immunol

Pays: Netherlands

ID NLM: 8102137

Informations de publication

Date de publication:
05 Aug 2024

Historique:

received: 01 05 2024

accepted: 26 07 2024

medline: 5 8 2024

pubmed: 5 8 2024

entrez: 5 8 2024

Statut: epublish

Résumé

Chronic granulomatous disease (CGD) is an inherited immunodeficiency caused by pathogenic variants of genes encoding the enzyme complex NADPH oxidase. In countries where tuberculosis (TB) is endemic and the Bacillus Calmette-Guérin (BCG) vaccine is routinely administered, mycobacteria are major disease-causing pathogens in CGD. However, information on the clinical evolution and treatment of mycobacterial diseases in patients with CGD is limited. The present study describes the adverse reactions to BCG and TB in Mexican patients with CGD. Patients with CGD who were evaluated at the Immunodeficiency Laboratory of the National Institute of Pediatrics between 2013 and 2024 were included. Medical records were reviewed to determine the clinical course and treatment of adverse reactions to BCG and TB disease. A total of 79 patients with CGD were included in this study. Adverse reactions to BCG were reported in 55 (72%) of 76 patients who received the vaccine. Tuberculosis was diagnosed in 19 (24%) patients. Relapse was documented in three (10%) of 31 patients with BGC-osis and six (32%) of 19 patients with TB, despite antituberculosis treatment. There was no difference in the frequency of BCG and TB disease between patients with pathogenic variants of the X-linked CYBB gene versus recessive variants. This report highlights the importance of considering TB in endemic areas and BCG complications in children with CGD to enable appropriate diagnostic and therapeutic approaches to improve prognosis and reduce the risk of relapse.

Identifiants

DOI: 10.1007/s10875-024-01778-7 PMID: 39102004

pubmed: 39102004

doi: 10.1007/s10875-024-01778-7

pii: 10.1007/s10875-024-01778-7

doi:

Substances chimiques

BCG Vaccine 0

NADPH Oxidase 2 EC 1.6.3.-

CYBB protein, human EC 1.6.3.-

Antitubercular Agents 0

NADPH Oxidases EC 1.6.3.-

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

Pagination

171

Informations de copyright

Références

Roos D. Chronic Granulomatous Disease. Methods Mol Biol. 1982;2019:531–42.

Rider NL, Jameson MB, Creech CB. Chronic Granulomatous Disease: Epidemiology, Pathophysiology, and Genetic Basis of Disease. J Pediatric Infect Dis Soc. 2018;7(suppl_1):S2–5.

doi: 10.1093/jpids/piy008 pubmed: 29746675 pmcid: 5946813

Marciano BE, Spalding C, Fitzgerald A, Mann D, Brown T, Osgood S, et al. Common severe infections in chronic granulomatous disease. Clin Infect Dis. 2015;60(8):1176–83.

doi: 10.1093/cid/ciu1154 pubmed: 25537876

Conti F, Lugo-Reyes SO, Blancas Galicia L, He J, Aksu G, de Oliveira Jr EB, et al. Mycobacterial disease in patients with chronic granulomatous disease: A retrospective analysis of 71 cases. J Allergy Clin Immunol. 2016;138(1):241-8.e3.

doi: 10.1016/j.jaci.2015.11.041 pubmed: 26936803

de Oliveira-Junior EB, Zurro NB, Prando C, Cabral-Marques O, Pereira PV, Schimke LF, et al. Clinical and Genotypic Spectrum of Chronic Granulomatous Disease in 71 Latin American Patients: First Report from the LASID Registry. Pediatr Blood Cancer. 2015;62(12):2101–7.

doi: 10.1002/pbc.25674 pubmed: 26185101

Fattahi F, Badalzadeh M, Sedighipour L, Movahedi M, Fazlollahi MR, Mansouri SD, et al. Inheritance pattern and clinical aspects of 93 Iranian patients with chronic granulomatous disease. J Clin Immunol. 2011;31(5):792–801.

doi: 10.1007/s10875-011-9567-x pubmed: 21789723

Koker MY, Camcioglu Y, van Leeuwen K, Kilic SS, Barlan I, Yilmaz M, et al. Clinical, functional, and genetic characterization of chronic granulomatous disease in 89 Turkish patients. J Allergy Clin Immunol. 2013;132(5):1156-63.e5.

doi: 10.1016/j.jaci.2013.05.039 pubmed: 23910690

Zhou Q, Hui X, Ying W, Hou J, Wang W, Liu D, et al. A Cohort of 169 Chronic Granulomatous Disease Patients Exposed to BCG Vaccination: a Retrospective Study from a Single Center in Shanghai, China (2004–2017). J Clin Immunol. 2018;38(3):260–72.

doi: 10.1007/s10875-018-0486-y pubmed: 29560547

Vignesh P, Sil A, Aggarwal R, Laha W, Mondal S, Dhaliwal M, et al. Tuberculosis and Bacillus Calmette-Guerin Disease in Patients with Chronic Granulomatous Disease: an Experience from a Tertiary Care Center in North India. J Clin Immunol. 2023;43(8):2049–61.

doi: 10.1007/s10875-023-01581-w pubmed: 37721651

Blancas-Galicia L, Santos-Chavez E, Deswarte C, Mignac Q, Medina-Vera I, Leon-Lara X, et al. Genetic, Immunological, and Clinical Features of the First Mexican Cohort of Patients with Chronic Granulomatous Disease. J Clin Immunol. 2020;40(3):475–93.

doi: 10.1007/s10875-020-00750-5 pubmed: 32040803

Kutukculer N, Aykut A, Karaca NE, Durmaz A, Aksu G, Genel F, et al. Chronic granulamatous disease: Two decades of experience from a paediatric immunology unit in a country with high rate of consangineous marriages. Scand J Immunol. 2019;89(2):e12737.

doi: 10.1111/sji.12737 pubmed: 30506560

Lee PP, Chan KW, Jiang L, Chen T, Li C, Lee TL, et al. Susceptibility to mycobacterial infections in children with X-linked chronic granulomatous disease: a review of 17 patients living in a region endemic for tuberculosis. Pediatr Infect Dis J. 2008;27(3):224–30.

doi: 10.1097/INF.0b013e31815b494c pubmed: 18277931

Graham SM, Cuevas LE, Jean-Philippe P, Browning R, Casenghi M, Detjen AK, et al. Clinical Case Definitions for Classification of Intrathoracic Tuberculosis in Children: An Update. Clin Infect Dis. 2015;61(Suppl 3):S179-87.

doi: 10.1093/cid/civ581 pmcid: 4583568

Leon-Lara X, Campos-Murguia A, Leon-Cabral P, Tello-Mercado A, Salgado-Nesme N, de la Mora JD, et al. Disseminated Tuberculosis in a Patient with Autosomal Recessive p47(phox) Chronic Granulomatous Disease. J Clin Immunol. 2021;41(6):1417–9.

doi: 10.1007/s10875-021-01057-9 pubmed: 34013431

Romero-Feregrino R, Romero-Cabello R, Rodriguez-Leon MA, Romero-Feregrino R, Munoz-Cordero B, Aguilar-Feregrino JI. Report of 16 Years of the BCG Vaccine under the Expanded Program on Immunizations in Mexico (2006–2021). Vaccines (Basel). 2023;11(2):337.

doi: 10.3390/vaccines11020337 pubmed: 36851215

Roy P, Vekemans J, Clark A, Sanderson C, Harris RC, White RG. Potential effect of age of BCG vaccination on global paediatric tuberculosis mortality: a modelling study. Lancet Glob Health. 2019;7(12):e1655–63.

doi: 10.1016/S2214-109X(19)30444-9 pubmed: 31708146 pmcid: 7024998

Yamazaki-Nakashimada MA, Unzueta A, Berenise Gamez-Gonzalez L, Gonzalez-Saldana N, Sorensen RU. BCG: a vaccine with multiple faces. Hum Vaccin Immunother. 2020;16(8):1841–50.

doi: 10.1080/21645515.2019.1706930 pubmed: 31995448 pmcid: 7482865

Sobh A, Bonilla FA. Vaccination in Primary Immunodeficiency Disorders. J Allergy Clin Immunol Pract. 2016;4(6):1066–75.

doi: 10.1016/j.jaip.2016.09.012 pubmed: 27836056

Deffert C, Schappi MG, Pache JC, Cachat J, Vesin D, Bisig R, et al. Bacillus calmette-guerin infection in NADPH oxidase deficiency: defective mycobacterial sequestration and granuloma formation. PLoS Pathog. 2014;10(9):e1004325.

doi: 10.1371/journal.ppat.1004325 pubmed: 25188296 pmcid: 4154868

Movahedi M, Aghamohammadi A, Rezaei N, Shahnavaz N, Jandaghi AB, Farhoudi A, et al. Chronic granulomatous disease: a clinical survey of 41 patients from the Iranian primary immunodeficiency registry. Int Arch Allergy Immunol. 2004;134(3):253–9.

doi: 10.1159/000078774 pubmed: 15178896

Deffert C, Cachat J, Krause KH. Phagocyte NADPH oxidase, chronic granulomatous disease and mycobacterial infections. Cell Microbiol. 2014;16(8):1168–78.

doi: 10.1111/cmi.12322 pubmed: 24916152

Cuello-Garcia CA, Perez-Gaxiola G. Jimenez Gutierrez C 2013 Treating BCG-induced disease in children. Cochrane Database Syst Rev. 2013;1:CD008300.

WHO | Global Tuberculosis Report 2020: World Health Organization; 2023 [Available from: https://www.who.int/teams/global-tuberculosis-programme/tb-reports . Accessed 7 Apr 2024.

van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS ONE. 2009;4(4):e5234.

doi: 10.1371/journal.pone.0005234 pubmed: 19381301 pmcid: 2668749

Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore). 2000;79(3):155–69.

doi: 10.1097/00005792-200005000-00003 pubmed: 10844935

Prince BT, Thielen BK, Williams KW, Kellner ES, Arnold DE, Cosme-Blanco W, et al. Geographic Variability and Pathogen-Specific Considerations in the Diagnosis and Management of Chronic Granulomatous Disease. Pediatric Health Med Ther. 2020;11:257–68.

doi: 10.2147/PHMT.S254253 pubmed: 32801991 pmcid: 7383027

Ishikawa T, Okai M, Mochizuki E, Uchiyama T, Onodera M, Kawai T. Bacillus Calmette-Guerin (BCG) Infections at High Frequency in Both AR-CGD and X-CGD Patients Following BCG Vaccination. Clin Infect Dis. 2021;73(9):e2538–44.

doi: 10.1093/cid/ciaa1049 pubmed: 32712647

Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. Clin Infect Dis. 2016;63(7):e147–95.

doi: 10.1093/cid/ciw376 pubmed: 27516382 pmcid: 6590850